Form 4: United Therapeutics Director Judy D. Olian Reports Acquisition of Restricted Stock Units

Director Judy D. Olian reports the acquisition of 1,190 restricted stock units in United Therapeutics Corporation.

Summary

• On July 25, 2024, Judy D. Olian, a director of United Therapeutics Corporation, acquired 1,190 restricted stock units (RSUs).
• These RSUs represent the right to receive one share of United Therapeutics Corporation common stock per unit following vesting.
• The RSUs were granted as an annual non-employee director award and will vest on July 25, 2025.
• Following the transaction, Ms. Olian directly owns 1,190 shares of common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of director compensation. The acquisition of RSUs is generally a positive sign, but it's a routine transaction.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be indicative of their confidence in the company's prospects.

Comparison to Industry Standards

• Director compensation packages often include restricted stock units to align the interests of directors with those of shareholders.
• The vesting period of one year is a common practice for RSU grants.

Stakeholder Impact

• The acquisition of RSUs by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates